Ipsen’s ambition is to be a leading global biotech company focused on innovation and Specialty Care.

Ipsen has implemented a strategy based on a sharpened focus in key therapeutic areas in Specialty Care, and the implementation of a sustainable Consumer Healthcare business through the OTx1 commercial model.
In Specialty Care, Ipsen is focused on three key therapeutic areas, Oncology, Neurosciences and Rare diseases, where Ipsen can establish a leadership position and leverage its expertise from drug development to commercialization. To complement the continued execution on its key products, including the important launches of Cabometyx® and Onivyde®, Ipsen has defined a targeted and dynamic innovation model to accelerate Specialty Care growth.

To build a sustainable pipeline of innovative assets, Ipsen will transform its R&D model by accelerating focused internal projects and externally sourcing assets.

Ipsen will continue to invest in business development through innovative deal structures with a focus on early to mid-stage assets in the three key therapeutic areas, targeting best-in-class, wholly-owned assets with global rights.

In Consumer Healthcare, to establish a sustainable and growing business, Ipsen will complete the OTx model transformation and leverage the three main market-leading brands through consumer innovations, capture the underlying market growth in emerging markets and strengthen the European business.


Implementing this strategy should allow Ipsen to see its sales keep growing as well as further improved profitability.

2020 outlook includes:

  • Sales greater than €2.5 billion, including Specialty Care sales growth of greater than 14% per year over the period 2016-2020 and Consumer Healthcare sales growth between 4% and 6% per year;
  • Core Operating Income margin greater than 30%.

This guidance includes the contribution from the recent 2017 acquisitions and excludes the impact from any further business development (other than development costs associated with potential new early to mid-stage R&D assets). It also covers the impact from potential Somatuline® competitive threats.


Last update 17/07/2018